LimFlow was founded in 2012 and has developed the world’s first system for creating a fully percutaneous Deep Vein Arterialization of the foot for the treatment of End Stage Critical Limb Ischemia.


Dan Rose


Dan Rose joined LimFlow in August of 2016 with over 16 years of leadership experience in the medical device and venture capital/startup sectors. Most recently, Dan was VP and General Manager EMEA for Direct Flow Medical, a leading innovator in Transcatheter Valves. Previously, he was VP of Commercial Operations and a Member of the Board at Sequana Medical, a Swiss medical device company with innovative implantable pump systems.

Dan also spent 8 years in leadership roles at Medtronic in the cardiovascular and cardiac surgery groups, including as Director of Marketing for Coronary Vascular EMEA and leading the Vascular Business unit in the Nordic Region. Earlier in his career, Dan cofounded a device company in the diabetes space and worked as an associate in London for a boutique life sciences VC, High Plains Investment Group. Dan has a BA and a MA from the University of Virginia and a MBA from the Darden Business School.

Tim Lenihan

Co-Founder & CTO

Tim Lenihan is the CTO and Co-Founder of LimFlow. Prior to founding LimFlow, Tim was CEO and Founder of Contract Medical International GmbH (CMI) a contract developer and manufacturer of catheter based medical devices headquartered in Dresden Germany with facilities in both Germany and the Czech Republic. Tim has worked in various engineering and regulatory positions in the medical device industry over the last 23 years both in the US and Europe. He has worked with researchers, entrepreneurs and small companies to develop, obtain approval, manufacture and launch of variety of medical devices in the field of Critical Care Medicine, Interventional Cardiology and Radiology and Respiratory Care.

Sophie Humbert


Sophie brings to LimFlow over 15 years of experience in the medtech industry with a strong track record of bringing innovation from scratch to market.  As a driven and structured entrepreneur, she was CEO and COO of a number of medtech start-up in cardiovascular, endovenous and oncology.  

Prior to joining LimFlow, Sophie was the COO of ART, an innovative and multicultural company designing bioresorbable stents for cardiovascular applications.  She helped the company earn CE mark for their first generation product and develop the second generation Drug Coated Bioresorbable stent. As a CEO of CermaVein, Sophie has successfully led the company from an early development stage, through CE marking and to commercialization in several markets.  Earlier in her career Sophie held R&D leadership position within Cerma and Bracco Diagnostics.

Her decisive focus on managing innovation combined with her strong track record is a key to bring LimFlow to success.

Sophie holds a PhD in Pharmaceutical Sciences from the University of Geneva, a Master Degree in Management from EM Lyon and a Pharma Doctorate from the University Claude Bernard in Lyon.

Thomas Engels

Vice President, Clinical Affairs

Thomas Engels has over 20 years of experience in the clinical research arena spanning pharma, biotech, and medical devices with 15+ years in interventional cardiology.  He has filled many different roles within clinical research.

Prior to joining LimFlow, Thomas held the Vice President of Clinical Affairs positions at Claret Medical (cerebral embolic protection for TAVI), Micell Technologies (next generation drug eluting stent), and CardioKinetix (transcatheter structural heart device intended to treat ischemic heart failure), taking novel devices through trials to achieve CE Mark, complete EU post-marketing safety surveillance, Chinese (CFDA) approval, as well as de novo clearance / PMA approval.  

Previously, Thomas served 10 years at Guidant Corporation / Abbott Vascular, as Director of Clinical Research he was responsible for a large portfolio of global  studies, ranging from small first-in-man trials to large post-marketing efforts. He had the opportunity to work on the predicate device trials through the PMA submission, FDA Panels, and launch of the XIENCE coronary stent. Mr. Engels holds a BS from Louisiana State University, MBA degrees from the Columbia Business School and the Haas School of Business, UC Berkeley.

Paul Limmer


Paul joins us from Direct Flow Medical, a leading innovator in Transcatheter Valves, where he led the European finance and administration functions.

Prior to this, Paul spent 17 years at General Electric and GE Capital, holding a variety of positions in Germany, including Finance Manager of GE Germany Technology, Finance Manager M&A and CFO of GE Capital Bank. Paul began his career as an auditor at Cargill Inc. and built his early finance skills at Siemens.

Paul is a Chartered Management Accountant (ACMA) and holds bachelor degrees from Leeds Metropolitan University and the Fachhochschule Bremen.